Tissue microarrays for high-throughput molecular pathology

Annals of Saudi Medicine

Volumn 24, Issue 3, 2004, Pages 169-174

  Al Kuraya, Khawla ^a   Simon, Ronald ^b   Sauter, Guido ^b  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DNA; PROTEIN; RNA;

CANCER MODEL; CANCER PATIENT; CELL LINE; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; DISEASE CLASSIFICATION; DNA MICROARRAY; ETHNIC DIFFERENCE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN MICROARRAY; REVIEW; RNA HYBRIDIZATION; STANDARDIZATION; VALIDATION PROCESS;

EID: 3142775809     PISSN: 02564947     EISSN: None     Source Type: Journal    
DOI: 10.5144/0256-4947.2004.169     Document Type: Review

References (53)

1. Venter JC, Adams MD, Myers EW, Li P, et al. The sequence of the human genome. Science. 2001;291: 1304-1351.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860-921.
3. Fejzo MS and Slamon DJ. Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. Am J Pathol. 2001;159:1645-1650.
4. Simon R and Sauter G. Tissue microarrays for miniaturized high-throughput molecular profiling of tumors. Exp Hematol. 2002;30:1365-1372.
5. Andersen CL, Monni O, Wagner U, et al. A. High-throughput copy number analysis of 17q23 in 3520 tissue specimens by fluorescence in situ hybridization to tissue microarrays. Am J Pathol. 2002;161:73-79.
6. Richter J, Wagner U, Kononen J, Fijan A, et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol. 2000;157:787-794.
7. Simon R, Richter J, Wagner U. Fijan A, et al. High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res. 2001;61:4514-4519.
8. Simon R, Struckmann K, Schraml P, et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene. 2002;21:2476-2483.
9. Kocher T, Zheng M, Bolli M, Simon R, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer. 2002;100:702-705.
10. Park SY, Kim HS, Hong EK, and Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-1085.
11. Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamaki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, and Kallioniemi OP. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst. 1999;91:1758-1764.
12. Saramaki O, Willi N, Bratt O, Gasser TC, Koivisto P, Nupponen NN, Bubendorf L, and Visakorpi T. Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am J Pathol. 2001;159:2089-2094.
13. Simon R, Nocito A, Hubscher T, Bucher C, Torhorst J, Schraml P, Bubendorf L, Mihatsch MM, Moch H, Wilber K, Schotzau A, Kononen J, and Sauter G. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst. 2001;93: 1141-1146.
14. Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, and Palotie A. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 2002;95:1247-1257.
15. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, and Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
16. Ginestier C, Charafe-Jauffret E, Bertucci F, Eisinger F, Geneix J, Bechlian D, Conte N, Adelaide J, Toiron Y, Nguyen C, Viens F, Mozziconacci MJ, Houlgatte R, Birnbaum D, and Jacquemier J. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol. 2002;161:1223-1233.
17. Poremba C, Heine B, Diallo R, Heinecke A, Wai D, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 2002;198:181-189.
18. Barlund M, Forozan F, Kononen J, Bubendorf L, Chen Y, Bittner ML, Torhorst J, Haas P, Bucher C, Sauter G, Kallioniemi OP, and Kallioniemi A. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252-1259.
19. Bucher C, Torhorst J, Kononen J, Haas P, Askaa J, et al. Automated, High-Throughput Tissue Microarray Analysis for Assessing the Significance of HER-2 Involvement in Breast Cancer. In: Proceedings of the ASCO annual meeting, 2000; Abstr. #2388, New Orleans, LA.
20. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159: 2249-2256.
21. Bubendorf L, Kononen J, Koivisto P, Schraml P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res. 1999;59:803-806.
22. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, and Chinnaiyan AM. Delineation of prognostic biomarkers in prostate cancer. Nature. 2001;412:822-826.
23. Mousses S, Bubendorf L, Wagner U, Hostetter G, Kononen J, et al. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res. 2002;62:1256-1260.
24. Miettinen HE, Jarvinen T A, Kellner U, et al. High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas. Neuropathol Appl Neurobiol. 2000;26:504-512.
25. Miettinen HE, Paunu N, Rantala I, Kalimo H, et al Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique. J Neurooncol. 2001;55:29-37.
26. Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, and Kononen J. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res, 2000;60:6617-6622.
27. Wang Y, Wu MC, Sham JS, Zhang, et al. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer. 2002;95: 2346-2352.
28. Moch H, Schraml P, Bubendorf L, Mirlacher M, Kononen J, et al. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol. 1999;154:981-986.
29. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, and Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res. 2001;7:4013-4020.
30. Hoos A, Nissan A, Stojadinovic A, Shia J, Hedvat CV, et al. Tissue Microarray Molecular Profiling of Early, Node-negative Adenocarcinoma of the Rectum: A Comprehensive Analysis. Clin Cancer Res. 2002;8: 3841-3849.
31. Otsuka M, Kato M, Yoshikawa T, Chen H, et al. Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis. Biochem Biophys Res Commun. 2001;289:876-881.
32. Garcia JF, Camacho FI, Morente M, et al. Hodgkin's and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue-microarrays. Blood. 2002;12: 12.
33. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, and Rimm DL. Tissue microarray-based analysis shows phospho-beta-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer. 2003;103:652-656.
34. Livingstone JI, Yasui W, Tahara E, and Wastell C. Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study. Br J Cancer. 1995;72:976-980.
35. Yosepovich A and Kopolovic J. Tissue microarray technology-a new and powerful tool for the molecular profiling of tumors. Harefuah. 2002;141:1039-1041, 1090.
36. Hendriks Y, Franken P, Dierssen JW, et al. Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors. Am J Pathol. 2003;162:469-477.
37. Tzankov A, Zimpfer A, Lugli A, Krugmann J, Went P, Schraml P, Maurer R, Ascani S, Pileri S, Geley S, and Dirnhofer S. High-throughput tissue microarray analysis of G1-cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1.J Pathol. 2003;199:201-207.
38. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
39. Nocito A, Bubendorf L, Maria Tinner E, Suess K, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001;194:349-357.
40. Rassidakis GZ, Jones D, Thomaides A, Sen F, Lai R, Cabanillas F, McDonnell TJ, and Medeiros LJ. Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. Am J Clin Pathol. 2002;118:328-334.
41. Hoos A, Urist MJ, Stojadinovic A, Mastorides S, Dudas ME, Leung DH, Kuo D, Brennan MF, Lewis JJ, and Cordon-Cardo C. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-1251.
42. Mucci NR, Akdas G, Manely S, and Rubin MA. Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays; to detect heterogeneous protein expression. Hum Pathol. 2000; 31:406-414.
43. Natkunam Y, Warnke RA, Montgomery K, Falini B, and van De Rijn M. Analysis of mum1/irf4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol. 2001;14:686-694.
44. Rubin MA, Dunn R, Strawderman M, and Pienta KJ. Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol. 2002;26:312-319.
45. Engellau J, Akerman M, Anderson H, et al. Tissue microarray technique in soft tissue sarcoma: immunohistochemical Ki-67 expression in malignant fibrous histiocytoma. Appl Immunohistochem Mol Morphol. 2001; 9:358-363.
46. Gulmann C, Butler D, Kay E, Grace A, and Leader M. Biopsy of a biopsy: validation of immunoprofiling in gastric cancer biopsy tissue microarrays. Histopathology. 2003; 42:70-76.
47. Hedvat CV, Hegde A, Chaganti et al. Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma. Hum Pathol. 2002;33:968-974.
48. Femebro E, Dictor M, Bendahl PO, Ferno M, and Nilbert M. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med. 2002;126:702-705.
49. Merseburger AS, Kuczyk MA, et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep. 2003;10:223-228.
50. Hoos A, Stojadinovic A, Mastorides S, Urist MJ, Polsky D, Di Como CJ, Brennan MF, and Cordon-Cardo C. High Ki-67 proliferative index predicts disease specific survival in patients with high-risk soft tissue sarcomas. Cancer. 2001;92:869-874.
51. Hoos A, Stojadinovic A, Singh B, Dudas ME, et al. Clinical significance of molecular expression profiles of Hurthle cell tumors of the thyroid gland analyzed via tissue microarrays. Am J Pathol. 2002;160:175-183.
52. Torhorst J, Bucher C, Kononen J, Haas P, Schraml P, Zuber M, Köchli O, Mross F, Dieterich H, Moch H, Milhatsch M, Kallioniemi O, and Sauter G. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol. 2001;159:2249-2256.
53. Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch M, Kallioniemi O, and Sauter G. Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res. 1999;5: 1966-1975.